Fig. 4From: Simultaneously inactivating Src and AKT by saracatinib/capivasertib co-delivery nanoparticles to improve the efficacy of anti-Src therapy in head and neck squamous cell carcinomaDifferential inactivation of AKT by saracatinib determines its therapeutic outcome for head and neck tumors in orthotopic xenograft mice. a–g were results from HN8-derived orthotopic xenograft mice, and h–n were results from HN12-derived orthotopic xenograft. a, h The effect of free (Sar) and NP-associated saracatinib (Nano-sar) on the phosphorylation levels of Src and AKT. b, i The effects of free and NP-associated saracatinib on cell viability. c, j The effects of free and NP-associated saracatinib on colony formation. d, k The effects of free and NP-associated saracatinib on 3D cell growth. e, l Tumor development and progression in mice receiving the indicated treatment monitored by examining bioluminescence in the Xenogen IVIS-200 In Vivo imaging system on Day 21. The representative images and quantitative data (n = 5) were shown in the left and right panels, respectively. f, m The representative images showing the size of tongue tumors in mice receiving the indicated treatment. g, n The levels of phospho-AKT in orthotopic xenograft tumors receiving different treatments determined by IHC. The representative IHC images were shown in the left panel, and quantification of IHC staining using Image pro-Plus6.0 was shown in right panel. *p < 0.05; **p < 0.01Back to article page